Author:
Stone A.M.,Bushnell W.,Denne J.,Sargent D.J.,Amit O.,Chen C.,Bailey-Iacona R.,Helterbrand J.,Williams G.
Reference32 articles.
1. FDA Oncologic Drugs Advisory Committee: endpoints for colorectal cancer regulatory approval. http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4037T2.DOC; 4th May, 2004.
2. FDA guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf; May 2007.
3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
4. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials;O’Shaugnessy;J Clin Oncol,1991
5. End points and United States Food and Drug Administration approval of oncology drugs;Johnson;J Clin Oncol,2003
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献